Aryan Caire, MD
Family Medicine · Santa Fe, NMNPI 1841426186
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$570
- Amgen$339
- Pfizer$317
- Lilly USA, LLC$283
- Boehringer Ingelheim$203
- AbbVie$193
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,927100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $570 |
| Amgen | 25 | $339 |
| Pfizer | 22 | $317 |
| Lilly USA, LLC | 17 | $283 |
| Boehringer Ingelheim | 12 | $203 |
| AbbVie | 10 | $193 |
| GSK | 15 | $173 |
| Astellas Pharma US Inc | 8 | $155 |
| Novo Nordisk | 8 | $136 |
| Teva Pharmaceuticals USA, Inc. | 6 | $112 |
| Novartis | 4 | $66 |
| Abbott | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Exact Sciences | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Healthtronics Stone Solutions, LLC | 1 | $23 |
| Merck | 2 | $23 |
| Gilead | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
How this compares
$2,927 in reported general payments places this provider in the 90th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $68,957 |
| TrulicityDulaglutide | 27 | $33,664 |
| JardianceEmpagliflozin | 21 | $23,196 |
| GemtesaVibegron | 19 | $23,080 |
| EliquisApixaban | 22 | $22,241 |
| FarxigaDapagliflozin Propanediol | 20 | $21,714 |
| XareltoRivaroxaban | 11 | $18,643 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $18,506 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,362 |
| Levothyroxine Sodium | 361 | $3,744 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,029 |
| Atorvastatin Calcium | 284 | $2,773 |
| SynthroidLevothyroxine Sodium | 41 | $2,565 |
| Rosuvastatin Calcium | 187 | $2,239 |
| Losartan Potassium | 215 | $2,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $136 | $68,95734 claims |
| Lilly USA, LLCTrulicity | $283 | $33,66427 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $173 | $26,89844 claims |
| Boehringer IngelheimJardiance | $203 | $23,19621 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $23,08019 claims |
| PfizerEliquis | $317 | $22,24122 claims |
| AstraZenecaFarxiga | $570 | $21,71420 claims |
| Johnson & JohnsonXarelto | $15 | $18,64311 claims |
| AbbVieSynthroid | $193 | $2,56541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Santa Fe
- Wendy JohnsonSanta Fe$37K
- Kurt KastendieckSanta Fe$7K
- Carl FriedrichsSanta Fe$7K
- Luis Rigales IiiSanta Fe$4K
- Debra HigginbothamSanta Fe$3K
- Karla Moya-CritesSanta Fe$3K
- Gerzain ChavezSanta Fe$3K
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.